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OBJECTIVES: Hepatitis C (HCV) can lead to serious and costly liver complications 
including hepatocellular carcinoma and liver transplantation. Physicians have 
employed a “watch and wait” philosophy, placing their HCV patients in “ware-
houses” depending on disease genotype (GT), waiting for disease progression 
or the launch of new treatments. There has been a significant amount of press 
behind the high prices of new HCV products, but little has been discussed about 
the cumulative clinical and economic value they bring. One aspect of value is 
clinical benefit as measured by sustained viral response (SVR) rate. The objective 
was to determine how the average efficacy, measured by SVR, of HCV treatments 
changed from November 2013 to April 2014 and its potential impact on clinical 
and economic outcomes. METHODS: Using IMS Health National Prescription Audit 
Data, two time periods were defined: the past state of November 2013, when the 
fewest number of prescriptions for HCV treatments were written; the current 
state of April 2014, when the greatest number of prescriptions for HCV treatments 
were written. In order to compare the average SVR rate in these two time points, 
we calculated a weighted average SVR rate across GTs based on the proportion of 
patients in each GT and the market share of the following products: sofosbuvir, 
telaprevir, simeprevir, and boceprevir. RESULTS: Combining SVR rates with market 
share and the proportion of patients in each GT, the average SVR rate in November 
2013 and April 2014 was 74% and 86%respectively. This 12% increase across GTs 
was presumably driven by the launch of sofosbuvir. CONCLUSIONS: There are 
significant clinical and economic implications of overall improvement in SVR 
rate including impacts on liver transplant hospitalizations and end of life care. 
Additional HEOR considerations related to linking SVR rates to these outcomes 
will be considered further in the poster.
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OBJECTIVES: Assess the clinical effect of clostridial collagenase ointment (CCO) 
relative to undifferentiated wound dressings in the outpatient care setting for the 
treatment of venous leg ulcers (VLU). METHODS: Retrospective de-identified elec-
tronic medical records from 2007-2013 were extracted from the Intellicure Limited 
Data Set (I-LDS). The I-LDS extracts records from 96 hospital-based outpatient 
wound centers. A propensity score model using a 3 to 1 nearest neighbor match-
ing approach was performed to test for treatment effect and adjust for covariance 
between that received CCO and wounds treated with undifferentiated wound dress-
ings. RESULTS: A total of 9,314 patients, 22,312 wounds, and 186,023 visits for VLU 
were identified. The majority of patients was female (51.9%) with an average age of 
61.6 (SD= 17.7). Approximately 21.3% had a history of hypertension, 8.3% had a his-
tory of venous insufficiency with diabetes, and 2.5% received immunosuppressive 
agents. The mean wound surface area was 7.9cm2 (SD= 14.4). The average wound 
age was 8.5 months (SD= 27.8) and the average treatment duration was 2.9 months 
(SD= 4.9). Of the 22,312 wounds, approximately 13.2% received CCO (n= 2,954). The 
average number of CCO tubes used by patients was 2.6 (SD = 1.2). The average total 
visits where CCO was administered was 5.6 (SD = 16.2) and the average days of use 
with CCO was 12.3 (SD = 41.3). VLUs treated with CCO were significantly more likely 
(p< 0.005) to improve over the course of therapy relative to wounds treated with 
undifferentiated wound dressings alone. CONCLUSIONS: This analysis indicates 
that CCO provides a clinical benefit in the management of VLUs. Over the course 
of therapy VLUs treated with CCO demonstrate greater clinical improvement than 
VLUs treated with undifferentiated wound dressings.
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OBJECTIVES: To indirectly estimate the relative treatment effect of 12 weeks of 
treatment with SMV versus TPV in combination with response-guided background 
therapy of 24/48 weeks of Peginterferon/ribavirine (PR) in previously untreated 
patients with genotype 1 chronic hepatitis C virus infection, using patient-level 
data from the pivotal phase III-trials. METHODS: Patient-level data from three 
phase 3 trials in treatment-naive patients were pooled: ADVANCE (12 weeks 
of TPV-treatment (T12PR24/48)) and QUEST 1&2 (12 weeks of SMV-treatment 
(SMV12PR24/48) (with PR24/48 meaning response-guided duration of PR of 24 or 
48 weeks). To adjust for potential differences in patient characteristics across both 
trials, an adjusted odds ratio (OR) for reaching sustained viral response at week 
24 (SVR24) was estimated for a multivariate logistic regression model, includ-
ing genotype (G1a vs G1b), liver status (F0-2 vs F3-4), race (white, black, other), 
viral load (< 273K/273-< 800K/800-< 1200K/≥ 1200K IU/ml), age (≤ 45/45< -≤ 65/> 65), 
gender and BMI (< 25/25-< 30/30+) as baseline covariates. As a sensitivity analy-
sis, a similar analysis was generated excluding SMV-G1a patients with Q80K-
polymorphism. RESULTS: Patient numbers for T12PR24/48 and SMV12PR24/48 
were 363 and 521 respectively. 16.3% (n= 85) of SMV-patients were G1a with Q80K-
polymorphism. Overall, G1a (OR vs 1b = 0.75, p= 0.01), peg-interferon alpha-2b (OR 
vs peg-interferon alpha-2a = 0.60, p= 0.03), F3-4 liver status (OR vs F0-F2= 0.48, 
p< 0.0001), black race (OR vs white race = 0.56, p< 0.001) and viral load ≥ 1200K (OR vs 
< 273K = 0.28, p< 0.0001) were significantly associated with lower SVR24-rates. The 
observed SVR24-rates were 75% (TVR) versus 80% (SMV) (unadjusted OR= 0.75). The 
adjusted OR for T12PR24/48 to reach SVR24 compared to SMV12PR24/48 was 0.64 
[95% CI: 0.46;0.91] (p= 0.0113). When excluding Q80K-positive patients, the adjusted 
OR was 0.45 [0.31;0.67] (p< 0.0001). CONCLUSIONS: In absence of H2H-comparison 
of telaprevir versus simeprevir in treatment-naive patients, an adjusted indirect 
commonly used antibiotics to manage cSSSI (vancomycin, linezolid, daptomycin, 
tigecycline). METHODS: This retrospective study was conducted using the Premier’s 
Perspective Comparative Database (2010-2013), which includes over 170 million 
inpatient records from ~500 hospitals in the US. Hospitalization records for adults 
(≥ 18 years) with a diagnosis of cSSSI (identified using ICD-9-CM codes) were selected. 
cSSSI-related hospitalization records with evidence of intravenous ceftaroline, vanco-
mycin, daptomycin, linezolid or tigecycline were included. Using four separate logistic 
regression models propensity scores were estimated and patients in ceftaroline group 
were matched with patients in vancomycin, daptomycin, linezolid and tigecycline 
groups separately. Outcomes including LOS, inpatient costs and in-hospital mortality 
were compared among patients in ceftaroline group with the 4 other antibiotic groups 
using unadjusted (t-test and chi-square tests) tests. RESULTS: The sample sizes in the 
matched cohorts were as follows: a) ceftaroline/ vancomycin n= 2,834 (each group); 
b) ceftaroline/daptomycin n= 2,651; c) ceftaroline/tigecycline n= 2,606; d) ceftaroline/
linezolid n= 2,554. Mean duration for the study antibiotics ranged from 3.9 (vanco-
mycin) to 4.6 (tigecycline) days. Average LOS and inpatients costs were significantly 
(all P-values < 0.001) lower among patents in the ceftaroline group compared with 
patients in the vancomycin (mean LOS: 5.1 vs. 5.6;costs: $8,051 vs. $10,089), linezolid 
(LOS: 5.1 vs. 6.4;costs: $8,081 vs. $12,020), daptomycin (LOS: 5.0 vs. 6.3;costs: $7,824 vs. 
$10,227), tigecycline (LOS: 5.2 vs. 6.1;costs: $8,264 vs. $11,353) groups. In-hospital mor-
tality rate was ~1% for ceftaroline, vancomycin, tigecycline and daptomycin groups 
(except linezolid group 2%). CONCLUSIONS: Previously two-large global clinical trials 
(CANVAS 1 and 2) confirmed clinical efficacy of ceftaroline in-comparison with vanco-
mycin (standard-of-care) among patients with cSSSI. The current study serves as an 
initial-step towards confirming real-world effectiveness of ceftaroline in comparison 
with other commonly used antibiotics for cSSSI.
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OBJECTIVES: New influenza vaccines were developed to improve vaccine effec-
tiveness by expanding influenza B coverage and boosting hemagglutinin (HA) 
concentration. This research aims to assess the health impact of the new vac-
cines – high dose (HD) and quadrivalent influenza vaccines (IIV4), instead of IIV3, 
in adults aged 65 and older under Ontario’s Universal Influenza Immunization 
Program (UIIP). METHODS: An analytical model of one flu season was developed 
using Ontario’s physician visits and ED uses, and Canadian influenza hospitaliza-
tion and mortality rates with three age cohorts (age 65-74, 75-84, and 85 and above) 
at two levels of health risks (high and low). Ontario’s demographic data was from 
Statistics Canada. Vaccine efficacy and effectiveness against health outcomes were 
based on published studies. Sensitivity analyses with extreme values of all relevant 
parameters were conducted. RESULTS: Use of HD in place of IIV3 would avert 13,271 
influenza cases (range: 4,648-23,161) and 2,483 symptomatic non-consulting cases 
(range: 690-5,226) annually, and decrease health care utilization significantly – 3,818 
physician office visits (range: 1,530-5,520), 1,223 emergency department (ED) uses 
(range: 485-1,786), 772 hospitalizations (range: 442-1,223) and 341 deaths (range 
195-537). These reductions in health outcomes would avoid 857 outpatient antiviral 
treatments (range: 0-2,192) and eliminate 4,546 days of lost productivity (range: 
1,387-10,054) among Ontario’s elderly residents a year. IIV4 also showed a reduction 
in influenza-related health outcomes – 4,900 influenza cases (range: 3,364-11,817), 
1,178 symptomatic non-consulting cases (range: 499-2,665), with 102 hospitaliza-
tions (range: 51-175) and 33 deaths (range 17-57) avoided annually; as a result, 1,623 
(623-3,928) work days loss were prevented. CONCLUSIONS: Although potential net 
health impact would fluctuate annually depending on the variability of influenza 
viruses, both HD and IIV4 are expected to attain significant to modest reductions 
in influenza-associated morbidity and mortality in seniors. Those findings were 
proven to be robust in sensitivity analyses.
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treatmeNt oN NeoNatal BaCterIal sePsIs
Tang L.
Suzhou Municipal Hospital, Suzhou, China
OBJECTIVES: Analyze the relationship of clinical efficacy and trough concentration 
of Vancomycin treatment on Neonatal Bacterial Sepsis according to the high trough 
concentration standards. METHODS: Totally 73 neonates with bacterial sepsis were 
selected in our hospital. Their clinical information,labotatory results and patho-
gens were collected. Statistical analysis of the clinical efficacy, bacterial clearance 
rate and plasma concentration data after vancomycin treatment. RESULTS: The 
clinical total effective rate and bacterial clearance rate were 86.30% and 91.78%.
The average trough concentration of vancomycin was(12.57±6.83)mg·L-1 . The rate 
of reaching the high trough concentration standards was only 41.1%. Compared 
to < 10mg·L-1, the bacterial clearance rate and clinical efficacy of trough concen-
tration in 10-20mg·L-1 were much higher (P= 0.013, P= 0.001). 24 cases adjusted 
the dose according to the initial concentration data, but only 13 cases(54.17%)’s 
trough concentrations were in the standard range. CONCLUSIONS: Clinical efficacy 
of Vancomycin has a good correlation with trough concentration. But the rate of 
reaching the high trough concentration standard was low and TDM is needed for 
individualized therapy regimen.
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and outcomes related to respiratory infection events were assembled monthly. 
Cox regressions were performed to determine hazard ratios (HRs) for hospitaliza-
tion. RESULTS: 12,137 infants (57.6% male, mean (SD) birth weight = 1585 (621)g, 
mean (SD) GA = 31.0 (2.9) weeks) were recruited and GA was categorized according 
to completed weeks: ≤ 26 weeks, 27-28 weeks, 29-30 weeks, 31-32 weeks, and 33-35 
weeks. Risk of RIH (HR, 95%CI) was significantly lower only in premature infants 
with GA ≤ 26 weeks (HR= 0.6, 0.4-1.0, p = .04). Risk of RSVH was significantly higher 
in infants with GA ≤ 26 weeks (HR = 4.2, 2.3-7.8, p < .0005), 27-28 weeks (HR = 2.3, 
1.2-4.1, p = .008), and 29-30 weeks (HR = 1.8, 1.0-3.0, p = .04) using 31-32 WGA as 
the comparator. CONCLUSIONS: Infants ≤ 30 WGA who received palivizumab 
had a significantly higher hazard for RSVH than those > 30 weeks. Lower RSVH 
hazard ratios in infants with higher GAs (> 30 weeks) are in agreement with the 
efficacy of palivizumab in this cohort (> 80% reduction in RSVH [32-35 weeks], 
IMpact trial) demonstrating that premature infants with lower GA are at highest 
risk following prophylaxis.
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OBJECTIVES: Modifiable factors contributable to disease progression and survival 
among people with HIV infection are of particular importance for HIV research. 
Hazardous drinking is one such variable associated with delayed linkage in care, 
increased HIV disease progression, worsened comorbidities (e.g., liver diseases). 
Curtailing hazardous drinking may have important survival implications. Few stud-
ies have explored the relationship among hazardous drinking, alcohol treatment 
and survival. We developed a computer simulation model predicting the survival 
influence of hazardous drinking and usage of alcohol treatment among individu-
als with HIV infection. METHODS: We simulated cohorts of 50,000 antiretroviral-
naïve hazardous drinkers with newly diagnosed chronic HIV infection. The model 
incorporated the influence of ART and distinguished AIDS-related deaths and non-
AIDS-related deaths (CVD, Cancer, Liver, and others). We modeled the impact of 
hazardous drinking on survival via its influence on viral suppression, and subse-
quent AIDS-related deaths, and mortality of various non-AIDS-related deaths. The 
role of alcohol treatment on survival was mediated through changes in hazardous 
drinking. The simulation model was a probabilistic, Monte-Carlo model created 
by Microsoft Excel 2010, and Oracle Crystal Ball 11. RESULTS: Hazardous drinking 
substantially reduced mean survival years and increased risk of dying due to liver 
diseases. For patients aged 35, hazardous drinkers had an average of 2.9 years lower 
in expected life years compared with those without hazardous drinking (30.4 years 
vs. 33.3 years). Receipt of alcohol treatment, regardless of behavioral treatment or 
pharmacotherapy, saved an average of 0.3 to 1.2 years per hazardous drinker when 
utilization rate varying from 10% to 80%. CONCLUSIONS: This study quantified 
deleterious effect of hazardous drinking in survival and provided evidence sup-
porting the survival benefits of using alcohol treatment. Given the high prevalent of 
hazardous drinking among individuals with HIV infection, interventions to decrease 
alcohol use may have great public health implications.
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OBJECTIVES: Identify patient and clinical characteristics in the diabetic foot 
ulcer (DFU) population and examine patterns of enzymatic debridement utiliza-
tion. METHODS: Retrospective, de-identified electronic medical records from 
2007-2013 were extracted from the Intellicure Limited Data Set (I-LDS). The I-LDS 
extracts records from 96 hospital-based outpatient wound centers. Patient, wound 
and encounter level characteristics were examined. The treatment of interest was 
enzymatic debridement with clostridial collagenase ointment (CCO). RESULTS: A 
total of 10,359 patients, 21,677 wounds, and 222,861 encounters for DFU were iden-
tified. The majority of patients was male (60.9%), Caucasian (63.5%), and reported 
Medicare as their primary insurance (51.1%). Of the 21,677 wounds, approximately 
16.9% received CCO (n= 3,670). Overall, the mean wound surface area was significantly 
larger (p< 0.0001) in DFUs treated with CCO (7.6cm2) compared to wounds not treated 
with CCO (5.4cm2), respectively. Wounds treated with CCO had significantly more 
(p< 0.001) debridements of all methods (5.4, SD= 6.3) relative to the overall population 
(4.3, SD= 6.1). Problems treated with CCO were significantly more likely (p< 0.0001) 
to have an infection (63.4%) compared to the overall DFU population (50.9%). The 
average number of visits where CCO was administered was 10.2 (SD= 9.7) and the 
average days of use with CCO was 53.2 days (SD= 68.9). The average number of CCO 
tubes used by patients was 2.4 (SD= 0.9). Mean days in service for CCO-treated wounds 
was 129.5 (SD= 149.1), which was significantly higher compared to days in service for 
non-CCO treated wounds (102.6, SD= 151.8). CONCLUSIONS: Wounds treated with 
CCO were larger, more likely to receive debridement of all methods, and more likely 
to be infected relative to the overall DFU population. Results from this analysis indi-
cate that health care providers are using CCO in more severe, difficult-to-heal DFUs.
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the treatmeNt of Pressure ulCers IN outPatIeNt Care settINgs
Gilligan A.M., Waycaster C.R.
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OBJECTIVES: Identify patient and clinical characteristics in the pressure ulcer (PU) 
population and examine patterns of enzymatic debridement utilization. METHODS: 
Retrospective, de-identified electronic medical records from 2007-2013 were extracted 
from the Intellicure Limited Data Set (I-LDS). The I-LDS extracts records from 96 
comparison using patient-level data suggests significantly higher SVR24 response 
rates for patients treated with simeprevir compared to telaprevir.
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OBJECTIVES: Tedizolid is a novel oxazolidinone approved for the treatment of 
ABSSSI. A network meta-analysis (NMA) was conducted to estimate the relative 
effectiveness and safety of tedizolid compared to other antibacterials for suspected 
or documented MRSA-associated ABSSSI. METHODS: A systematic review identified 
relevant randomized controlled trials of tedizolid and other antibacterials approved 
to treat complicated skin infections (cSSSI, cSSTI, and ABSSSI) caused by suspected 
or documented MRSA in adults (vancomycin, linezolid, daptomycin, teicoplanin, 
tigecycline, ceftaroline, and telavancin). Two independent reviewers extracted 
study characteristics and outcomes, including clinical response at post-treatment 
evaluation (generally 7-14 days following therapy) and adverse events (AE)-related 
treatment discontinuations. Bayesian NMA was conducted for each outcome using 
fixed and random effects models. RESULTS: 3,618 records were identified. 15 trials 
met inclusion criteria. In fixed effect models, tedizolid had higher odds of clinical 
response at PTE or TOC than vancomycin (odds ratio [OR]: 1.6 [95% credible inter-
val: 1.1, 2.5]), corresponding to absolute response rates of 87% [9%, 100%] and 80% 
[5%, 100%], respectively. No statistically significant differences in odds of clinical 
response between tedizolid and other comparators were observed. Results were 
similar when limited to intent-to-treat (ITT) or microbiological ITT analysis popula-
tions. In an ad hoc analysis of MRSA-only populations, ORs for response were 1.0, 1.2, 
2.1, 1.1, 3.2, and 1.6 for tedizolid versus linezolid, ceftaroline, daptomycin, telavancin, 
tigecycline, and vancomycin, respectively. , . Absolute rates of discontinuation due to 
AEs ranged from 0.3% [0%, 49%] for tedizolid to 1.2% [0%, 81%] for telavancin, but no 
comparisons reached statistical significance. Results from fixed and random effects 
models generally were consistent. CONCLUSIONS: These findings suggest that tedi-
zolid offers an alternative treatment option for serious skin infections caused by 
suspected or documented MRSA. This study is subject to limitations inherent to all 
NMAs, and the results should be interpreted accordingly.
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ClINICal ComParIsoN of full Course INtraveNous or aBBrevIated 
oral aNtIBIotICs IN hosPItalIzed PatIeNts wIth methICIllIN-
resIstaNt s. aureus (mrsa) skIN aNd soft tIssue INfeCtIoNs
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OBJECTIVES: Orally active MRSA drugs are utilized in hospitalized patients for 
treatment of skin infections to abridge intravenous (IV) therapy, but clinical evi-
dence of their effectiveness is needed. Our goal was to compare health outcomes 
in hospitalized adult patients treated with a full course of IV or abbreviated oral 
antibiotics for MRSA skin infections. METHODS: This was a single center, retro-
spective cohort study of hospitalized patients with culture positive MRSA skin 
infections managed from 2009-2013. Patients were stratified based on receipt of 
full course IV antibiotics or abbreviated oral antibiotics during the hospital stay. 
Treatment failure was defined as one of the following within 90 days of initiation 
of treatment: 1. additional MRSA culture from any site, 2. change in antibiotic 
therapy, 3. secondary incision and drainage. Statistical analysis included multivari-
ate logistic regression models to assess for predictors of failure. RESULTS: Among 
101 patients with MRSA skin infections, 60 received a full course of IV antibiotics 
and 41 converted to oral antibiotics (minocycline or doxycycline [n= 34]). Treatment 
failure at 90 days was 35%, occurrence of failure was similar among patients with 
a full course of IV therapy and those abbreviated to oral therapy (21 of 60 [35%] vs. 
14 of 41 [34%], p = 0.93). The length of IV therapy was significantly less in patients 
treated with oral therapy (6.5 days vs 4 days, p< 0.01). In the multivariate adjusted 
model, treatment with oral antibiotics was not associated with failure. Predictors 
of failure included Hispanic ethnicity (aOR 15.8; 95% CI, 1.8-138.9, P = 0.01) and a 
trend towards significance for ulcer skin infections (p = 0.052). CONCLUSIONS: 
Although hospitalized patients are commonly treated with full course IV antibi-
otics for MRSA skin infections, we found similar outcomes in those converted to 
oral antibiotics. Treatment failures were associated with Hispanic ethnicity and 
ulcer skin infections.
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ProPhylaxed wIth PalIvIzumaB IN the CaNadIaN regIstry of 
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BACKGROUND: The efficacy and safety of palivizumab for respiratory syncytial 
virus (RSV) prophylaxis in healthy premature infants ≤ 35 weeks gestational age 
(WGA), was confirmed in the IMpact, randomized trial. However, there are lim-
ited data on the incidence of hospitalization for respiratory related events in 
prophylaxed infants in the lower GA sub-categories. OBJECTIVES: The primary 
objective is to evaluate the incidence of respiratory illness (RIH) and RSV-specific 
hospitalizations (RSVH) in high-risk premature infants who received palivi-
zumab. METHODS: Data were collected from premature infants ≤ 35 completed 
WGA enrolled in the CARESS registry, who received at least one palivizumab injec-
tion between the 2005-2014 RSV seasons. Palivizumab utilization, compliance, 
